Please login to the form below

Not currently logged in
Email:
Password:

BMS melanoma drug meets goal

Bristol-Myers Squibb has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study

Bristol-Myers Squibb (BMS) has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study.

The trial, known as study 024, showed that ipilimumab improved overall survival in previously untreated patients with unresectable stage III or stage IV melanoma. The trial compared the BMS drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

BMS said it plans to submit an abstract of the data to the American Society of Clinical Oncology for presentation at the society's Annual Meeting this summer.

BMS has already filed the drug with the US Food and Drug Administration (FDA), as well as regulatory authorities in a number of other countries, as a therapy for previously treated unresectable stage III or stage IV melanoma patients. In the US, a decision regarding the drug for that indication is due within days.

22nd March 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....